Skip to main content
SpringerLink
Log in

Assessment of ventricular function by radionuclide angiography in patients receiving 4′-epidoxorubicin and mitoxantrone

  • Original Articles
  • Cardiotoxicity, 4′-Epidoxorubicin, Mitoxantrone
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Serial assessment of ventricular function by means of radionuclide angiography was performed in 50 patients with malignant neoplasms who received either 4′-epidoxorubicin or mitoxantrone for longer than 3 months.

In 9 of 30 patients give 4′-epidoxorubicin, a decrease of ≥10% in the left ventricular ejection fraction (LVEF) was documented at doses of 143–1200 mg/m2. Two patients developed clinical signs of cardiotoxicity at a dose of >1000 mg/m2.

In 6 of 20 patients given mitoxantrone a decrease of ≥10% in the LVEF occurred at doses of 26–98 mg/m2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Arcamone F, Penco S, Vigevani A, Redaelli S, Franchi G, Di Marco A, Casazza AM, Dasdia T, Formelli F, Necco A, Soranzo C (1975) Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone. J Med Chem 18: 703–707

    Google Scholar 

  2. Benjamin RS, Chawla SP, Ewer MS, Carrasco CH, Mackay B, Haynie (III) TP, Yap HY, Blumenschein GR, Holmes F, Ali MK, Bodey GP (1984) Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy. Proc Am Soc Clin Oncol 3: 40

    Google Scholar 

  3. Bishop J, Hillcoat B, Raghavan D, Jeal P, Coates A, Wood R, Snyder R (1984) Mitomycin C, mitoxantrone in previously treated patients with advanced breast cancer. Proc Am Soc Clin Oncol 3: 116

    Google Scholar 

  4. Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, Gasazza AM (1979) Preliminary phase I study of 4′-Epi-Adriamycin. Cancer Treat Rep 63: 915–918

    Google Scholar 

  5. Bonfante V, Villani F, Bonadonna G (1982) Toxic and therapeutic activity of 4′-epi-doxorubicin. Tumori 68: 105–111

    Google Scholar 

  6. Casazza AM (1979) Experimental evaluation of anthracycline analogs. Cancer Treat Rep 63: 835–844

    Google Scholar 

  7. Casazza AM, DiMarco A, Bonadonna G, Bonfante V, Bertazzoli C, Bellini O, Pratesi G, Sala L, Ballerini L (1980) Effects of modifications in position 4 of the chromophore or in position 4′ of the aminosugar, on the antitumor activity and toxicity of daunorubicin and doxorubicin. In: Crooke ST, Reich SD (eds) Anthracyclines: current status and new developments. Academic, New York, pp 403–430

    Google Scholar 

  8. Crossley RJ (1983) Clinical safety and tolerance of mitoxantrone (Novantrone). Cancer Treat Rev 10 [suppl B]: 29–36

    Google Scholar 

  9. Dantchev D, Slioussartchok V, Paintrand M, Bourut D, Mathé G, Madeira-Coelho A (1980) Ultrastructural study of the cardiotoxicity and light microscopic findings of the skin after treatment of golden hamsters with seven different anthracyclines. Recent Results Cancer Res 74: 223–249

    Google Scholar 

  10. Falkson G, Vorobiof DA (1984) 4′-epidoxorubicin in colorectal cancer. In: Bonadonna G (ed), Advances in anthracycline chemotherapy: Epirubicin. Masson, Milano, pp 105–109

    Google Scholar 

  11. Foster B, Lev L, Bergmann C, Claggett-Carr C, Marsoni S (1984) Cardiac events in patients treated with mitoxantrone in phase II trials sponsored by the National Cancer Institute. Proc Am Assoc Cancer Res 25: 168

    Google Scholar 

  12. Gottdiener JS, Mathisen DJ, Borer JS, Bonon RO, Myers C, Barr LH, Schwartz DE, Bacharach SL, Green MV, Rosenberg SA (1981) Doxorubicin cardiotoxicity: Assessment of late ventricular dysfunction by radionuclide cineangiography. Ann Intern Med 94: 430–435

    Google Scholar 

  13. Greenberg BH, Dren D, Botvinick EH, Werner JA, Klausner SC, Shames DM, Parmley WM (1980) Evaluation of left ventricular performance by gated radionuclide angiography. Clin Nucl Med 5: 245–254

    Google Scholar 

  14. Henderson BM, Dougherthy WJ, James VC, Tilley LP, Noble JF (1982) Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs compared with doxorubicin: I. Clinical observations. Cancer Treat Rep 66: 1139–1143

    Google Scholar 

  15. Henderson IC, Dukart G (1984) A randomized trial comparing mitoxantrone with doxorubicin in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 3: 120

    Google Scholar 

  16. Holmes F, Yap H, Buzdar A, Esparza L, Hortobagyi G, Blumenshein G, Ho DH, Bodey G (1984) Sequential chemotherapy with mitoxantrone, cyclophosphamide and fluorouracil followed by doxorubicin and vinblastine in advanced breast cancer. Proc Am Soc Clin Oncol 3: 124

    Google Scholar 

  17. Iturralde M, Van Aswegen A (1982) Radionuclide imaging and determination of ventricular function. In: Anghileri LJ (ed) General processes of radiotracer localization, vol 2, chap 2, CRC Press, Boca Raton

    Google Scholar 

  18. Jain JJ, Casper ES, Geller NL, Hakes TB, Kaufman RJ, Currie V, Schwartz W, Cassidy C, Petroni GR, Young CW, Wittes RE (1985) A prospective randomized comparison of doxorubicin and a less cardiotoxic analog, epirubicin, in patients with advanced breast cancer, submitted to Ann Intern Med

  19. Kennedy JW, Sorensen SG, Ritchie JL, Folland ED, Hamilton GW (1978) Radionuclide angiography for the evaluation of anthracycline therapy. Cancer Treat Rep 62: 941–943

    Google Scholar 

  20. Lefrak EA, Pitha J, Rosenheim S, Gottlieb J (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302–314

    Google Scholar 

  21. Maksymiuk AW, Bowman DM, Bodhurta AJ (1984) Mitoxantrone plus tamoxifen versus tamoxifen for metastatic breast cancer. Proc Am Soc Clin Oncol 3: 124

    Google Scholar 

  22. Murdock KC, Wallace RE, Durr FE, Child RG, Citarella RV, Fabio PF, Angier RB (1979) Antitumor agents: I. 1,4-Bis-(aminoalkylamino)-9, 10-anthracenediones. J Med Chem 22: 1024–1030

    Google Scholar 

  23. Okada RD, Pohost GM, Nicols AB, McKusik KA, Strauss HW, Boucher CA, Block PC, Rosenthal SV, Dinsmore RE (1980) Left ventricular regional wall motion assessment by multigated and end diastolic end systolic gated radionuclide left ventriculography. Am J Cardiol 45: 1211–1218

    Google Scholar 

  24. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K (1985) Mitoxantrone: An Overview of Safety and Toxicity. Investigational New Drugs 3: 123–132

    Google Scholar 

  25. Ritchie JL, Singer JW, Thorming D, Sorensen SG, Hamilton GW (1980) Anthracycline cardiotoxicity: Clinical and pathologic outcomes assessed by radionuclide ejection fraction. Cancer 46: 1109–1116

    Google Scholar 

  26. Rosso R, Nobile MT, Campora E, Conte PF, Chiara S, Muttini P, Fiorio P, Calciati A, Giaccone G, Clerico M, De Filippi PG, Picciotto G (1984) Comparative evaluation of cardiac toxicity of doxorubicin and 4′-epidoxorubicin, In: Bonadonna G (ed) advances in anthracycline chemotherapy: Epriubicin. Masson, Milano, p 19

    Google Scholar 

  27. Schauer PK, Wittes RE, Gralla RJ, Casper ES, Young CW (1981) A phase I trial of 4′-epi-adriamycin. Cancer Clin Trials 4: 433–437

    Google Scholar 

  28. Sparano BM, Gordon G, Hall C, Iatropoulos MJ, Noble JF (1982) Safety assessment of a new anticancer compound, mitoxantrone, in beagle dogs: Comparison with doxorubicin: II. Histologic and ultrastructural pathology. Cancer Treat Rep 66: 1145–1158

    Google Scholar 

  29. Torti FM, Bristaw Bristaw MR, Howes AE, Aston D, Kohler M, Mitchell EP, Meyers FJ, Billingham ME (1984) Preliminary observations of epirubicin cardiac toxicity: methodologic considerations in the evaluation of doxorubicin and its analogs by endomyocardial biopsy, In: Bonadonna G (ed) advances in anthracycline chemotherapy: Epirubicin. Masson, Milano, p 20

    Google Scholar 

  30. Van Aswegen A, Herbst CP, Lötter MG, Otto AC, Kleynhans PHT, Minaar PC (1983) Variation in left ventricular ejection fraction determination at rest and during exercise. S Afr Med J 63: 890–892

    Google Scholar 

  31. Van Echo DA, Leone LA, Davis R, Santomauro B, Henderson E, Frei E (1984) A phase II study of mitoxantrone (NSC 301739) in patients with primary liver cancer. Proc Am Soc Clin Oncol 3: 143

    Google Scholar 

  32. Villani F, Favalli C, Piccinini F (1980) relationship between the effect on calcium turnover and early cardiotoxicity of doxorubicin and 4′-epidoxorubicin in guinea pig heart muscle. Tumori 66: 689–697

    Google Scholar 

  33. Villani F, Comazzi R, Guindani A, Crippa F (1984) Myocardial toxicity of 4′-epidoxorubicin: The experience of the National Cancer Institute of Milan. In: Bonadonna G (ed) advances in anthracycline chemotherapy: Epirubicin. Masson, Milano, p 17

    Google Scholar 

  34. Von Hoff DD, Layard MW, Basa P, Davis H, von Hoff A, Rozencweig M, Muggia F (1979) Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 91: 710–717

    Google Scholar 

  35. Vorobiof DA, Iturralde M, Falkson G (1983) Amsacrine cardiotoxicity: Assessment of ventricular function by radionuclide angiography. Cancer Treat Rep 67: 115–117

    Google Scholar 

  36. Vorobiof DA (1984) Radionuclide ventriculography for the assessment of left ventricular function in patients receiving cancer chemotherapy. Cancer Ther Update 4: 3

    Google Scholar 

  37. Wilson KS, Paterson AHG (1984) Single-agent mitoxantrone as first-line chemotherapy in advanced breast cancer. Proc Am Soc Clin Oncol 3: 117

    Google Scholar 

  38. Young CW, Casper ES, Geller NC (1984) Clinical and cineangiographic comparison of the cardiotoxic effects of epirubicin and doxorubicin, In: Bonadonna G (ed) advances in anthracycline chemotherapy: Epirubicin. Masson, Milano, p 18

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cancer Chemotherapy, University of Pretoria, Pretoria, Republic of South Africa

    Daniel A. Vorobiof & Geoffrey Falkson

  2. Department of Nuclear Medicine, University of Pretoria, Pretoria, Republic of South Africa

    Mario Iturralde

Authors
  1. Daniel A. Vorobiof
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mario Iturralde
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Geoffrey Falkson
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This study was supported in part by a grant from the National Cancer Association of South Africa

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vorobiof, D.A., Iturralde, M. & Falkson, G. Assessment of ventricular function by radionuclide angiography in patients receiving 4′-epidoxorubicin and mitoxantrone. Cancer Chemother. Pharmacol. 15, 253–257 (1985). https://doi.org/10.1007/BF00263896

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00263896

Keywords

Search

Navigation